Article
Selective therapeutic strategy for p53-deficient cancer by targeting dysregulation in DNA repair.
Communications biology - 12 Jul 2021
Zonneville Justin, Wang Moyi, Alruwaili Mohammed M, Smith Brandon, Melnick Megan, Eng Kevin H, Melendy Thomas, Park Ben Ho, Iyer Renuka, Fountzilas Christos, Bakin Andrei V
Abstract excerpt
Breast carcinomas commonly carry mutations in the tumor suppressor p53, although therapeutic efforts to target mutant p53 have previously been unfruitful. Here we report a selective combination therapy strategy for treatment of p53 mutant cancers. Genomic data revealed that p53 mutant cancers exhibit high replication activity and express high levels of the Base-Excision Repair (BER) pathway, whereas experimental...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.